title: D3 dopamine receptor directly interacts with D1 dopamine receptor in immortalized renal proximal tubule cells.
abstract: D3 receptors act synergistically with D1 receptors to inhibit sodium transport in renal proximal tubules; however, the mechanism by which this occurs is not known. Because dopamine receptor subtypes can regulate and interact with each other, we studied the interaction of D3 and D1 receptors in rat renal proximal tubule (RPT) cells. The D3 agonist PD128907 increased the immunoreactive expression of D1 receptors in a concentration- and time-dependent manner; these effects were blocked by the D3 antagonist U99194A. PD128907 also transiently (15 minutes) increased the amount of cell surface membrane D1 receptors. Laser confocal immunofluorescence microscopy showed that D3 receptor and D1 receptor colocalized in RPT cells more distinctly in Wistar-Kyoto rats than in spontaneously hypertensive rats (SHRs). In addition, D3 and D1 receptors could be coimmunoprecipitated, and this interaction was increased after D3 receptor agonist stimulation for 24 hours in Wistar-Kyoto rats but not in SHRs. We propose that the synergistic effects of D3 and D1 receptors may be caused by a D3 receptor-mediated increase in total, as well as cell surface membrane D1 receptor expression, and direct D3 and D1 receptor interaction, both of which are impaired in SHRs.
authors.affiliation: Department of Cardiology, Daping Hospital, Third Military Medical University, Chongqing, People's Republic of China. cyzeng1@hotmail.com
authors.forename: Chunyu
authors.initials: C
authors.lastname: Zeng
authors.forename: Zheng
authors.initials: Z
authors.lastname: Wang
authors.forename: Hewang
authors.initials: H
authors.lastname: Li
authors.forename: Peiying
authors.initials: P
authors.lastname: Yu
authors.forename: Shaopeng
authors.initials: S
authors.lastname: Zheng
authors.forename: Lijuan
authors.initials: L
authors.lastname: Wu
authors.forename: Laureano D
authors.initials: LD
authors.lastname: Asico
authors.forename: Ulrich
authors.initials: U
authors.lastname: Hopfer
authors.forename: Gilbert M
authors.initials: GM
authors.lastname: Eisner
authors.forename: Robin A
authors.initials: RA
authors.lastname: Felder
authors.forename: Pedro A
authors.initials: PA
authors.lastname: Jose
mesh_terms: D000818:Animals; D001578:Benzopyrans / Q000494:pharmacology; D002461:Cell Line, Transformed; D002462:Cell Membrane / Q000378:metabolism; D018491:Dopamine Agonists / Q000494:pharmacology; D018492:Dopamine Antagonists / Q000494:pharmacology; D004347:Drug Interactions; D006973:Hypertension / Q000378:metabolism*; D047468:Immunoprecipitation; D007189:Indans / Q000494:pharmacology; D007687:Kidney Tubules, Proximal / Q000378:metabolism*; D018613:Microscopy, Confocal; D008856:Microscopy, Fluorescence; D010078:Oxazines / Q000494:pharmacology; D051381:Rats; D011918:Rats, Inbred SHR; D011921:Rats, Inbred WKY; D017447:Receptors, Dopamine D1 / Q000378:metabolism*; D050637:Receptors, Dopamine D3 / Q000819:agonists / Q000037:antagonists & inhibitors / Q000378:metabolism*; D014018:Tissue Distribution
chemical_list: D001578:Benzopyrans; D018491:Dopamine Agonists; D018492:Dopamine Antagonists; D007189:Indans; D010078:Oxazines; D017447:Receptors, Dopamine D1; D050637:Receptors, Dopamine D3; C062458:3,4,4a,10b-tetrahydro-4-propyl-2H,5H-(1)benzopyrano(4,3-b)-1,4-oxazin-9-ol; C086335:(5,6-dimethoxyindan-2-yl)dipropylamine